Growing old is a natural and beautiful part of life, shaped by experiences and wisdom. Yet aging is a complex, multifactorial phenomenon that impacts many interrelated biological pathways. At Rejuvenate Biomed, we embrace the complexity of aging and focus on the healthcare challenge posed by age-related diseases. Our approach to drug discovery and development starts from navigating the  pathways that underlie human aging, also known as the hallmarks of aging¹. 

¹ López-Otín et al., Cell (2023)

Rejuvenate Biomed developed two proprietary drug discovery platforms:

• CombinAge®, an AI-enabled in silico platform to discover drug combinations that have the highest potential to treat age-related diseases
• CelegAge®, an in vitro and in vivo platform, using living organism C. elegans and cell culture to evaluate the impact of synergistic drug combinations on healthspan markers

Prediction data obtained from our platforms are confirmed in established preclinical models and in clinical studies.

Our three key success factors:

• We impact multiple aging pathways simultaneously by developing combination drugs
• We increase probability of success by using CombinAge® and CelegAge®
• We de-risk and shorten the development process by starting from drugs with established human safety profile
• We secore strong patent protection

RJx-01 is a proprietary combination drug:

• Proprietary formulation for oral administration
• Synergistic effect of 2 small molecules
• Patent protected for multiple indications
• Established human safety profile
• Improvements in human model on muscle strength, function, and fatigue resistance
• Unique PK profile

Preclinical research showed that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models¹. These data validate the predictive value of our proprietary drug discovery platforms and have accelerated the advancement of RJx-01 into a first clinical study in healthy elderly subjects. In this successful Phase 1b trial in disuse-induced muscle atrophy, RJx-01 met all primary and secondary endpoints. RJx-01 was generally safe and well tolerated with no reported treatment-related serious or severe adverse events. The proprietary and innovative RJx-01 formulation exhibited excellent bioavailability. The exploratory endpoints showed improvements on muscle strength, function, and fatique resistance. RJx-01 is currently under evaluation in COPD-induced sarcopenia (Phase 2 trial fully enrolled) with data expected by year-end 2026. 

Sarcopenia is the progressive loss of physical performance, skeletal muscle strength and mass, affecting up to 1 in 5 older adults globally² and there are no approved drug treatments.

¹Tezze et al, JCI (2022)
² Dent et al, J Nutr Health Aging​ (2018)